Dr. Berz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8900 Wilshire Blvd
Beverly Hills, CA 90211Phone+1 310-432-8900- Is this information wrong?
Education & Training
Brown UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Norwalk Hospital/Yale UniversityResidency, Internal Medicine, 2002 - 2005
Humboldt University of Berlin - Charite Faculty of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2011 - 2025
LA State Medical License 2012 - 2015
RI State Medical License 2005 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours Start of enrollment: 2018 May 03
Publications & Presentations
PubMed
- 6 citationsMRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony...> ;Journal of Thoracic Oncology. 2023 Jul 1
- 22 citationsRandomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider, Jerome H. Goldschmidt, Jennifer L. Eisenstein, David Berz, Lasika Senevi...> ;Journal of Thoracic Oncology. 2021 Feb 1
- 62 citationsSafety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.James Chih-Hsin Yang, D. Ross Camidge, Cheng-Ta Yang, Jianying Zhou, Renhua Guo, Chao Hua Chiu, Gee-Chen Chang, Her Shyong Shiah, Yuan Chen, Chin Chou Wang, David Berz...> ;Journal of Thoracic Oncology. 2020 Dec 1
- Join now to see all
Press Mentions
Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy MeetingOctober 1st, 2020
G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 CongressSeptember 10th, 2019
Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal MetastasesDecember 6th, 2016- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Beverly HospitalMontebello, California
- PIH Health Downey HospitalDowney, California
Lakewood Regional Medical CenterLakewood, California
PIH Health Whittier HospitalWhittier, California- Whittier Hospital Medical CenterWhittier, California
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
